Literature DB >> 16568241

The clinical potential of sphingolipid-based therapeutics.

T E Fox1, C M Finnegan, R Blumenthal, M Kester.   

Abstract

The era of sphingolipid-based therapeutics is upon us. A large body of work has been accumulating that demonstrates the distinct biological roles of sphingolipids in maintaining a homeostatic environment and in responding to environmental stimuli to regulate cellular processes. It is thus necessary to further investigate alterations in sphingolipid-metabolism in pathological conditions and, in turn, try to exploit altered sphingolipid-metabolizing enzymes and their metabolites as therapeutic targets. This review will examine how advances in the fields of drug delivery, drug discovery, synthetic chemistry, enzyme replacement therapy, immunobiology, infectious disease and nanotechnology have delivered the potential and promise of utilizing and/or targeting sphingolipid metabolites as therapies for diverse diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16568241     DOI: 10.1007/s00018-005-5543-z

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  14 in total

Review 1.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

2.  Enhanced tumor cures after Foscan photodynamic therapy combined with the ceramide analog LCL29. Evidence from mouse squamous cell carcinomas for sphingolipids as biomarkers of treatment response.

Authors:  D Separovic; J Bielawski; J S Pierce; S Merchant; A L Tarca; G Bhatti; B Ogretmen; M Korbelik
Journal:  Int J Oncol       Date:  2010-12-06       Impact factor: 5.650

3.  TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis.

Authors:  Keith R Stayrook; Justin K Mack; Donna Cerabona; Daniel F Edwards; Hai H Bui; Maria Niewolna; Pierrick Gj Fournier; Khalid S Mohammad; David L Waning; Theresa A Guise
Journal:  Bonekey Rep       Date:  2015-07-08

4.  Serine palmitoyltransferase inhibitor myriocin induces growth inhibition of B16F10 melanoma cells through G(2) /M phase arrest.

Authors:  Y-S Lee; K-M Choi; M-H Choi; S-Y Ji; S Lee; D-M Sin; K-W Oh; Y-M Lee; J-T Hong; Y-P Yun; H-S Yoo
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

5.  Examining impacts of ceranib-2 on the proliferation, morphology and ultrastructure of human breast cancer cells.

Authors:  Djanan Vejselova; Hatice Mehtap Kutlu; Gökhan Kuş
Journal:  Cytotechnology       Date:  2016-07-05       Impact factor: 2.058

6.  Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells.

Authors:  Mark Kester; Yasser Heakal; Todd Fox; Arati Sharma; Gavin P Robertson; Thomas T Morgan; Erhan I Altinoğlu; Amra Tabaković; Mylisa R Parette; Sarah M Rouse; Victor Ruiz-Velasco; James H Adair
Journal:  Nano Lett       Date:  2008-12       Impact factor: 11.189

Review 7.  Roles of bioactive sphingolipids in cancer biology and therapeutics.

Authors:  Sahar A Saddoughi; Pengfei Song; Besim Ogretmen
Journal:  Subcell Biochem       Date:  2008

Review 8.  Gaucher's disease and cancer: a sphingolipid perspective.

Authors:  Brian M Barth; Sriram S Shanmugavelandy; Diana M Tacelosky; Mark Kester; Samy A F Morad; Myles C Cabot
Journal:  Crit Rev Oncog       Date:  2013

9.  Sphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusion.

Authors:  Catherine M Finnegan; Satinder S Rawat; Edward H Cho; Danielle L Guiffre; Stephen Lockett; Alfred H Merrill; Robert Blumenthal
Journal:  J Virol       Date:  2007-03-07       Impact factor: 5.103

10.  Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas.

Authors:  D Separovic; J Bielawski; J S Pierce; S Merchant; A L Tarca; B Ogretmen; M Korbelik
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.